Opus Genetics, Inc. cotiza a 4.64 USD y tiene una capitalización bursátil de $386M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phas…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.08 | $-0.75 | $-0.21 |
| Estimado | $-0.15 | $-0.16 | $-0.14 | $-0.10 |
| Sorpresa | — | +50.0% | -435.7% | -110.0% |
| Métrica | IRD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -271.9% | -38.6% | -233.3% |
| Net Margin | -349.3% | -33.6% | -315.8% |
| FCF Margin | — | -13.9% | — |
| ROE | -323.1% | -40.4% | -282.7% |
| ROA | -98.7% | -32.0% | -66.7% |
| Current Ratio | 6.43 | 2.84 | +3.59 |
| Debt / Equity | 0.07 | 0.28 | -0.21 |